The team’s findings indicate that OPN silencing results in the inhibition of various downstream effector cascades, involving a reduced expression of urokinase plasminogen activator, VEGF, MMP-2 and MMP-9, which in turn may clinically translate into a reduction in colon cancer invasion, angiogenesis and metastasis. This evidence concerns the gene SPP1 and colonic neoplasm.